BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006;:CD002095. [PMID: 16855986 DOI: 10.1002/14651858.CD002095.pub3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Potgieter W, Samuels CS, Snyman JR. Potentiated clinoptilolite: artificially enhanced aluminosilicate reduces symptoms associated with endoscopically negative gastroesophageal reflux disease and nonsteroidal anti-inflammatory drug induced gastritis. Clin Exp Gastroenterol 2014;7:215-20. [PMID: 25061329 DOI: 10.2147/CEG.S51222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
2 Holtmann G, Bigard MA, Malfertheiner P, Pounder R. Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD. Int J Clin Pharm. 2011;33:493-500. [PMID: 21472476 DOI: 10.1007/s11096-011-9489-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
3 Hongo M, Kinoshita Y, Haruma K. A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease. J Gastroenterol 2008;43:448-56. [PMID: 18600389 DOI: 10.1007/s00535-008-2186-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
4 Monaco L, Brillantino A, Torelli F, Schettino M, Izzo G, Cosenza A, Martino ND. Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive to proton pump inhibitors. World J Gastroenterol 2009; 15(3): 334-338 [PMID: 19140233 DOI: 10.3748/wjg.15.334] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
5 Modlin I, Hunt R, Malfertheiner P, Moayyedi P, Quigley E, Tytgat G, Tack J, Heading R, Holtman G, Moss S. Diagnosis and Management of Non-Erosive Reflux Disease – The Vevey NERD Consensus Group. Digestion 2009;80:74-88. [DOI: 10.1159/000219365] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 6.7] [Reference Citation Analysis]
6 Lord RV, DeMeester SR, Peters JH, Hagen JA, Elyssnia D, Sheth CT, DeMeester TR. Hiatal hernia, lower esophageal sphincter incompetence, and effectiveness of Nissen fundoplication in the spectrum of gastroesophageal reflux disease. J Gastrointest Surg. 2009;13:602-610. [PMID: 19050984 DOI: 10.1007/s11605-008-0754-x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 59] [Article Influence: 6.1] [Reference Citation Analysis]
7 Zhu Q, Liu WZ. Advances in roles of prokinetic agents in the treatment of gastroesophageal reflux disease. Shijie Huaren Xiaohua Zazhi 2008; 16(7): 737-745 [DOI: 10.11569/wcjd.v16.i7.737] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Leiman DA, Riff BP, Morgan S, Metz DC, Falk GW, French B, Umscheid CA, Lewis JD. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus 2017;30:1-9. [PMID: 28375448 DOI: 10.1093/dote/dow020] [Cited by in Crossref: 55] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
9 Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009;2:295-314. [PMID: 21822447 DOI: 10.1586/ecp.09.8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
10 Khan Z, Alastal Y, Khan MA, Khan MS, Khalil B, Shrestha S, Kamal F, Nawras A, Howden CW. On-Demand Therapy with Proton Pump Inhibitors for Maintenance Treatment of Nonerosive Reflux Disease or Mild Erosive Esophagitis: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2018;2018:6417526. [PMID: 30158966 DOI: 10.1155/2018/6417526] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;CD002095. [PMID: 23728637 DOI: 10.1002/14651858.cd002095.pub5] [Cited by in Crossref: 50] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
12 Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med. 2008;359:1700-1707. [PMID: 18923172 DOI: 10.1056/nejmcp0804684] [Cited by in Crossref: 190] [Cited by in F6Publishing: 60] [Article Influence: 13.6] [Reference Citation Analysis]
13 Epstein D, Bojke L, Sculpher MJ; REFLUX trial group. Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study. BMJ 2009;339:b2576. [PMID: 19654097 DOI: 10.1136/bmj.b2576] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
14 Green CJ, Maclure M, Fortin PM, Ramsay CR, Aaserud M, Bardal S. Pharmaceutical policies: effects of restrictions on reimbursement. Cochrane Database Syst Rev 2010;:CD008654. [PMID: 20687098 DOI: 10.1002/14651858.CD008654] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
15 Lima JJ, Lang JE, Mougey EB, Blake KB, Gong Y, Holbrook JT, Wise RA, Teague WG. Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. J Pediatr 2013;163:686-91. [PMID: 23623526 DOI: 10.1016/j.jpeds.2013.03.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
16 Liakakos T, Karamanolis G, Patapis P, Misiakos EP. Gastroesophageal reflux disease: medical or surgical treatment? Gastroenterol Res Pract. 2009;2009:371580. [PMID: 20069112 DOI: 10.1155/2009/371580] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
17 Nwokediuko SC. Current trends in the management of gastroesophageal reflux disease: a review. ISRN Gastroenterol. 2012;2012:391631. [PMID: 22844607 DOI: 10.5402/2012/391631] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
18 Matuz M, Benkő R, Engi Z, Schváb K, Doró P, Viola R, Szabó M, Soós G. Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics. Front Pharmacol 2020;11:552102. [PMID: 33013389 DOI: 10.3389/fphar.2020.552102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Tan VP, Wong WM, Cheung TK, Lai KC, Hung IF, Chan P, Pang R, Wong BC. Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial. J Gastroenterol 2011;46:906-12. [PMID: 21538030 DOI: 10.1007/s00535-011-0402-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
20 Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951. [PMID: 18679668 DOI: 10.1007/s00228-008-0538-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 188] [Article Influence: 14.6] [Reference Citation Analysis]
21 Kang SJ, Jung HK, Tae CH, Kim SY, Lee KJ. On-demand Versus Continuous Maintenance Treatment of Gastroesophageal Reflux Disease With Proton Pump Inhibitors: A Systematic Review and Meta-analysis. J Neurogastroenterol Motil 2022;28:5-14. [PMID: 34980685 DOI: 10.5056/jnm21095] [Reference Citation Analysis]
22 Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. 2007;CD001216. [PMID: 17253456 DOI: 10.1002/14651858] [Cited by in Crossref: 2625] [Cited by in F6Publishing: 769] [Article Influence: 175.0] [Reference Citation Analysis]
23 Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med. 2008;359:1700-1707. [PMID: 18923172 DOI: 359/16/1700] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S, Ashida K, Ohara S, Kashiwagi H, Adachi K, Higuchi K, Miwa H, Fujimoto K, Kusano M, Hoshihara Y, Kawano T, Haruma K, Hongo M, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751-767. [PMID: 27325300 DOI: 10.1007/s00535-016-1227-8] [Cited by in Crossref: 142] [Cited by in F6Publishing: 115] [Article Influence: 23.7] [Reference Citation Analysis]
25 Moreira Dias L. Pantoprazole: a proton pump inhibitor. Clin Drug Investig 2009;29 Suppl 2:3-12. [PMID: 19938880 DOI: 10.2165/1153121-S0-000000000-00000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Jung DH, Huh CW, Lee SK, Park JC, Shin SK, Lee YC. A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil 2021;27:165-75. [PMID: 33795539 DOI: 10.5056/jnm20161] [Reference Citation Analysis]
27 Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. Strategy for treatment of nonerosive reflux disease in Asia. World J Gastroenterol 2008; 14(20): 3123-3128 [PMID: 18506915 DOI: 10.3748/wjg.14.3123] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]